Physician profile
Christos Sidiropoulos
NPI 1972794774
$20,711.13
in general payments reported to CMS, 2019-2025
25 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,911 · 2021: $1,588 · 2022: $161 · 2023: $497 · 2024: $1,075 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,996.69 | 2019-2025 | Duopa |
| Boston Scientific Corporation | $5,705.25 | 2019-2024 | |
| Acorda Therapeutics, INC | $2,405.21 | 2019-2023 | Inbrija |
| Medtronic USA, INC. | $531.16 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $385.48 | 2022-2025 | Qelbree |
| Acadia Pharmaceuticals INC | $349.03 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $261.28 | 2019-2025 | Ingrezza |
| Biogen, INC. | $163.93 | 2020-2024 | Skyclarys, Tysabri, Skyclarys |
| Kyowa Kirin, INC. | $154.02 | 2023-2024 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $114.49 | 2024 | Dysport |
| Amneal Pharmaceuticals LLC | $89.03 | 2023-2025 | Crexont, Rytary |
| Teva Pharmaceuticals USA, INC. | $72.16 | 2019 | |
| Cala Health, INC. | $72.08 | 2022-2024 | Cala Kiq, Cala Trio |
| Medtronic, INC. | $69.82 | 2021-2025 | Percept Pc Brainsense |
| Abbott Laboratories | $60.91 | 2019-2023 | Infinity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $58.32 | 2023-2025 | Nayzilam, Kygevvi, Rystiggo |
| Merz Pharmaceuticals, LLC | $48.50 | 2025 | Inbrija, Xeomin |
| Lundbeck LLC | $46.87 | 2019 | |
| Avion Pharmaceuticals | $32.37 | 2021-2022 | |
| Tg Therapeutics, INC. | $27.38 | 2025 | |
| Aucta Pharmaceuticals, INC. | $19.35 | 2025 | Motpoly Xr |
| Revance Therapeutics, INC. | $18.26 | 2024 | Daxxify |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.33 | 2022 | |
| Neurelis, INC. | $13.21 | 2023 | Valtoco |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christos Sidiropoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.